News

Formatech has selected Kai Pharmaceuticals (Kai) and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program. Formatech plans to complete

Under these licensing agreements, EraGen will have access to Illumina’s BeadXpress platform for the continued development and commercialisation of molecular-based, high-throughput clinical multiplexed assays with its unique, patented

Takeda Pharmaceutical (Takeda) has reported that TAK-438, an acid-related diseases drug, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.

The Food and Drug Administration (FDA) has warned patients against taking Nexium or Prilosec if they are already taking Plavix. Plavix, a prescribed blood thinner that protects against

IntelGenx has announced the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The

The US House of Representatives, and the Society of Chemical Manufacturers and Affiliates (SOCMA) have urged Congress to avoid sweeping changes to the Toxic Substances Control Act (TSCA)

Purdue Pharma and Napp Pharmaceutical have filed a patent infringement petition against Sun Pharmaceuticals and its US subsidiary. The litigation was filed following a para IV certification filed

Aterovax has announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD)

Novartis has reported new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US